spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  angiotensin II 

 HSMN NewsFeed - 10 Dec 2020
ReCor Medical Announces Positive Results in RADIANCE-HTN TRIO Study and Breakthrough Device Designation for Paradise(TM) Ultrasound Renal Denervation System
Devices Cardiology FDA
 HSMN NewsFeed - 24 Aug 2017
Thomas Eklund New Chairman of Pharmalink
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Aug 2017
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2017
Pharmalink AB Announces the Appointment of a New Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2016
Allergan Announces FDA Approval of BYVALSON(TM) (nebivolol and valsartan)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 3 Jun 2014
Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 May 2014
Spinifex Pharmaceuticals Strengthens Scientific Advisory Board (SAB) with Experts in Chronic Pain
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2014
Genkyotex Announces New Senior Management and Board Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2014
Iroko’s ZORVOLEX(TM) Now Available
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 22 May 2013
Par Pharmaceutical Begins Shipment of Generic Atacand(R)
Biopharmaceuticals Cardiology Generics Distribution
 HSMN NewsFeed - 23 Aug 2011
Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Jul 2010
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jul 2010
Trevena Secures $35 Million in Series B Funding to Progress Portfolio of GPCR Biased Ligands and to Complete Phase 2 Study of TRV120027 for Acute Heart Failure
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Jun 2010
New Head-to-Head Phase 3 Study Evaluated Systolic Blood Pressure Reduction of Investigational Compound Azilsartan Medoxomil Compared to Valsartan
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 May 2010
FDA Approved VIMOVO(TM) for Arthritis Patients at Risk of Developing NSAID-Associated Gastric Ulcers
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 11 Feb 2010
FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 19 Oct 2009
FDA Approves New Use for Micardis(R) in Cardiovascular Risk Reduction and Twynsta(R) as New Combination Treatment for High Blood Pressure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 13 May 2009
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2009
New Data Shows Blood Pressure Reduction Therapy With BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
Biopharmaceuticals
 HSMN NewsFeed - 8 May 2009
New Data Shows AZOR(R) (Amlodipine and Olmesartan Medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Jan 2009
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge in France
Biopharmaceuticals
 HSMN NewsFeed - 16 Jun 2008
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2008
New Data Shows 45 Percent of Patients With Stage 1 Hypertension Reached Normotension With BENICAR(R) and BENICAR HCT(R)
Biopharmaceuticals
 HSMN NewsFeed - 1 Apr 2008
SPP100 (Tekturna/Rasilez) Reduces Left Ventricular Hypertrophy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Mar 2008
Landmark Trial ONTARGET(R) Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High-Risk Cardiovascular Population. From ONTARGET(R) it May be Concluded That Telmisartan can Prevent Every 5th Serious Cardiovascular Event
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 Feb 2008
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 21 Jan 2008
US Approval for SPP100 Combined with Diuretic to Treat Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jan 2008
NitroMed Reports on BiDil XR(TM) Progress Following FDA Meeting, Announces Restructuring and Suspension of BiDil(R) Sales Force, and Retains Investment Bank to Advise on Strategic Options
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2007
Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
Biopharmaceuticals
 HSMN NewsFeed - 19 Nov 2007
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve BP Goals
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 27 Sep 2007
AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Sep 2007
Study Data Shows Gaps and Variation in the Use of Evidence-Based Treatments and Guidelines for Chronic Heart Failure
Devices Cardiology
 HSMN NewsFeed - 27 Aug 2007
SPP100 (Rasilez) Receives EU Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Jun 2007
Exforge(R) Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jun 2007
CardioDynamics Announces New ICG Hypertension Evidence
Devices Monitoring Cardiology
 HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Mar 2007
Tekturna(R), First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 Mar 2007
EVEREST Data on Short- and Long-Term Use of Otsuka's Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC's Late Breaking Clinical Trials
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Dec 2006
Exforge(R) Receives US Regulatory Approval as a New and Highly Effective Treatment Option for Patients with High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Oct 2006
Plexxikon and Servier Signed Cardiovascular Collaboration
Biopharmaceuticals
 HSMN NewsFeed - 17 May 2006
New Phase III Data on Renin Inhibitor SPP100 (Rasilez) in Treatment of Hypertension Demonstrates Potential of This First-in-Class Drug
Biopharmaceuticals
 HSMN NewsFeed - 4 May 2006
Combined Use of ATACAND(R) (candesartan cilexetil) and ACE Inhibitor Improves Heart Failure Outcomes More Than ACE Inhibitor Alone
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 50

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 50 additional stories matching:
angiotensin II
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.